sc0062
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 23, 2023 (NCT05687890)
Timeline
Indications
Mechanism of action
- Endothelin receptor ET-AANTAGONIST
EDNRA antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06819826 | Phase 3 | Feb 14, 2025 | Biocity Biopharmaceutics Co., Ltd. |
| NCT05687890 | Phase 2 | May 23, 2023 | Biocity Biopharmaceutics Co., Ltd., Zhejiang University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biocity Biopharmaceutics Co., Ltd. | For profit | 2 | 2 | 2 | 2023 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1